We are live on
!
Find out more
Atara Biotherapeutics
ATRA
ATRA
86 hedge funds and large institutions have $519M invested in Atara Biotherapeutics in 2017 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 29 increasing their positions, 24 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
40% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 10
21% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 24
18% more capital invested
Capital invested by funds: $441M → $519M (+$77.7M)
5% more funds holding
Funds holding: 82 → 86 (+4)
0.42% more ownership
Funds ownership: 3.48% → 3.9% (+0.42%)
74% less call options, than puts
Call options by funds: $750K | Put options by funds: $2.85M
Holders
86
Holders Change
+4
Holders Change %
+4.88%
% of All Funds
1.95%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
29
Reduced
24
Closed
10
Calls
$750K
Puts
$2.85M
Net Calls
-$2.1M
Net Calls Change
-$2.55M
Top Buyers
| 1 |
BM
Bridger Management
New York
|
+$14M |
| 2 |
AG
Artal Group
Luxembourg
|
+$5.91M |
| 3 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$5.48M |
| 4 |
Morgan Stanley
New York
|
+$4.42M |
| 5 |
NC
Nexthera Capital
New York
|
+$4.23M |
Top Sellers
| 1 |
Neuberger Berman Group
New York
|
-$1.52M |
| 2 |
RI
RTW Investments
New York
|
-$1.48M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$1.47M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$1.09M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$764K |
